Although co-inhibition of CD38 and PD-L1 improves antitumor immune response in NSCLC as previously reported (2), the co-inhibition did not demonstrate anti-tumor effects in a SCLC mouse model in this study. This evidence concerns the gene CD38 and neoplasm.